Educational guide
Autoimmune Diseases | JPT Peptides
Autoimmune Diseases About Autoimmune Diseases Abnormal immune responses directed towards the body's own proteins (self-antigens) Leads to tissue damage 80 types of autoimmune diseases known such as systemic lupus erythematosus, celiac disease, diabetes mellitu
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Autoimmune Diseases
About Autoimmune Diseases
Abnormal immune responses directed towards the body's own proteins (self-antigens)
Leads to tissue damage
80 types of autoimmune diseases known such as systemic lupus erythematosus, celiac disease, diabetes mellitus type 1, Graves' disease, multiple sclerosis and rheumatoid arthritis
Causes are mostly unknown, diagnosis can be difficult
Treatments can improve symptoms
Autoimmune diseases cannot be cured
Diabetes & Obesity
One of the most common autoimmune diasese is Diabetes. Diabetes is an endocrine disease leading to very high blood sugar levels caused by either the pancreas not producing enough insulin (diabetes type 1 or insulin-dependent diabetes mellitus), or the cells of the body becoming insulin resistant (diabetes type 2 or insulin-dependent diabetes mellitus). Peptides can contribute:
Use of C-peptides in diagnostics
Insulin replacement therapies
Peptide-based treatment like semaglutide or GLP-1 receptor agonists
Target & Epitope Discovery
Target and epitope discovery represent major challenges to enable early diagnosis and the development of suitable treatment strategies. JPT possesses a variety of unique high-throughput peptide-based technologies enabling deep discovery of relevant targets as well as systematic discovery of B- and T-cell epitopes.
In addition, our ultra-fast and cost efficient peptide synthesis strategies together with sophisticated bioinformatics approaches enable sequence diversity considerations (splice variants, mutations etc.) and post-translational modifications that have not previously been addressed from proteome-spanning perspectives.
JPT's Autoimmune Peptide Formats
Filter products
B-cell Immunity
Cancer biomarker research
Cosmetics
Diabetes research
Enzymology
Nuclear medicine
Protein-protein-interaction
T-cell immunity
Abeta Peptides
Antigen Peptides
Chelate Peptides (DOTA)
Cosmetic Peptides (DPRA Peptides)
Custom Peptides
Diabetes Peptides
Enzyme Substrate Arrays
Enzyme Substrate Sets
Micro-Scale Peptides
PepMix Collections
PepMix Pan Select Peptide Pools
PepMix Peptide Pools
PepMix Peptide Pools Controls
PepMix Peptide Pools Infections
PepMix Peptide Pools TAA
PepMix Peptide Pools other Antigens
PepMix Ultra Peptide Pools
PepStar Peptide Microarrays
Sirtuin Substrates
Acetyltransferase
Adenocarcinoma
Arthritis
Autoimmune disease
Breast cancer
Cancer
Celiac disease
Cellulitis
Diabetes
Diabetes mellitus
Diarrhea
Fever
Gene editing
Gene therapy
Hepatitis
Hepatocellular carcinoma
Hypoxia
Immunogenic
Infection
Leukemia
Lung cancer
Lyme disease
Lymphoma
Melanoma
Metabolism
Multiple sclerosis
Myasthenia gravis
Ovarian cancer
Prediabetes
Prostate cancer
Psoriasis
Respiratory disease
Rubella
Spondylitis
Vitiligo
non-Hodgkin lymphoma
Artificial
Clostridium tetani
Coxsackievirus
Escherichia coli
Heloderma suspectum
Human
Influenza A
M. tuberculosis
Streptococcus pyogenes
Triticum aestivum
Alpha/beta-gliadin
CRISPR-associated endonuclease Cas9/Csn1
Capsid protein
Diabetes Peptide
GLP-1
Glucagon
Glucose-6-phosphatase
Glutamate carboxypeptidase
Glutamate decarboxylase
Glutamate decarboxylase 2 (GAD2)
Glutamine synthetase
HLA class II antigen
HLA class I antigen
Hypoxia-inducible lipid droplet-associated protein
Insulin
Keratin
Melanocyte protein Pmel 17 (gp100)
Melanoma antigen recognized by T-cells 1 (MART-1)
Myelin basic protein
Myelin proteolipid protein
Myosin
Protein
RNA-binding protein
Selected proteins
Tetanus Toxin
Tyrosine-protein kinase
Vimentin
No
Yes
Custom PepMix™ Peptide Pools
Custom PepStar™ Peptide Microarrays
Custom Peptide Synthesis
PepTrack™ Peptide Libraries
SpotMix Antigen Discovery Pools
(Asp28)-Glucagon (1-29), Human, CAS: 1037751-81-7
US$884.00
(D-His1)-Liraglutide - GLP1 receptor agonist
(Des-Gly4)-Liraglutide - GLP1 receptor agonist
(Des-Thr7)-Glucagon, CAS: 1802078-28-9
(Glu20)-Glucagon (1-29), Human, CAS: 2022956-46-1
Discovery
Cellular Immune Response
Humoral Immune Response
References
Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigenspecific autoimmune diseasesSaggau et al., Immunity (2024) - PMID: 39226901Product used: PepMix™ Human (MOG)
Human antibody profling technologies for autoimmune diseaseCarlton et al., Immunologic Research (2023)Product used: Custom PepStar Peptide Microarrays & PepSpots Peptides on Cellulose
Expression of Programmed Death Ligand (PD-L1) in Different Tumors. Comparison of Several Current Available Antibody Clones and Antibody ProfilingKintsler et al., Annals of Diagnostic Pathology (2019)
First-Trimester Proteomic Profiling Identifies Novel Predictors of Gestational Diabetes MellitusRavnsborg et al, PLoS One (2019)
Trapped in the Epineurium: Early Entry Into the Endoneurium is Restricted to Neuritogenic T Cells in Experimental Autoimmune NeuritisMausberg et al, Journal of Neuroinflammation (2018)